The latest catalyst for Alphamab Oncology (SEHK:9966) is the U.S. FDA granting Breakthrough Therapy Designation to its HER2 targeting ADC JSKN003 for difficult to treat, platinum resistant ovarian ...
The average one-year price target for Alphamab Oncology (SEHK:9966) has been revised to HK$10.20 / share. This is an increase of 42.86% from the prior estimate of HK$7.14 dated December 3, 2025. The ...
2617.HK TransThera Sciences (Nanjing), Inc.
Alphamab Oncology (9966) Alphamab Oncology stock price live, this page displays HK 9966 stock exchange data. View the 9966 premarket stock price ahead of the market session or assess the after hours ...
1877.HK Shanghai Junshi Biosciences Co., Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback